The Application of Prostate Specific Membrane Antigen in the Diagnosis and Treatment of Prostate Cancer: Status and Challenge

Tongwei Zeng; Yongqiang Xie; Keqiang Chai; Hui Sang

doi:10.2147/OTT.S485869

The Application of Prostate Specific Membrane Antigen in the Diagnosis and Treatment of Prostate Cancer: Status and Challenge

Onco Targets Ther. 2024 Nov 14:17:991-1015. doi: 10.2147/OTT.S485869. eCollection 2024.

Authors

Tongwei Zeng^#¹, Yongqiang Xie^#¹, Keqiang Chai¹, Hui Sang¹

Affiliation

¹ Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, 730900, People's Republic of China.

^# Contributed equally.

Abstract

In recent years, the incidence of prostate cancer has been increasing globally. Early stage of the disease can obtain a better clinical prognosis from surgery and endocrine therapy. The progression of advanced stage varies significantly between individuals, with some patients developing metastatic castration-resistant prostate cancer after standardized treatment. Therefore, staging of prostate cancer by accurate imaging is particularly important for the clinical management of patients. Simultaneously, the development of targeted therapy is also urgent for the treatment of advanced prostate cancer. Prostate specific membrane antigen as a prostate specific target has been widely used in the diagnosis and treatment of prostate cancer. This review summarizes the latest research progress of targeted prostate specific membrane antigen in the diagnosis and treatment of prostate cancer in detail, analyzes their value and challenges.

Keywords: CAR-T; DCs vaccine; PET; PSMA; prostate cancer; radioligand therapy.

Publication types

Review

Grants and funding

This work was supported by Baiyin Science and Technology Plan Project (Clinical Application research on early screening of Prostate cancer in Baiyin Area: 2022-3-6Y) and Baiyin First People’s Hospital Science and Technology Plan Project (2019YK-08).